TM4SF5 and metabolic dysfunction-associated steatohepatitis: In addition to the many different therapeutic targets of chronic liver disease, including NASH and HCC, which are currently being explored by different global pharmaceutical industries, it could be worthwhile exploring other targets, including TM4SF5 and its binders.